Recreational Drug Use Linked to 9-Fold Higher Rate of Adverse Outcomes in Intensive Cardiac Care
Various illicit substances were detected in urine assays of 1 in 10 patients admitted to cardiac intensive care, according to findings of new French study.
Novel Neurostimulation Device Shows Significant Benefit for Migraine
The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.
Asundexian Granted FDA Fast Track Designation for Stroke Prevention in Patients with AF
Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.
Eisai Seeks Traditional FDA Approval for Lecenemab with Supplemental BLA Filing
Approval of lecanemab under FDA's accelerated pathway requires the company to provide phase 4 study evidence to confirm the agent's clinical effect.
